文献速递精神分裂症与精神病性障碍

精神分裂症多基因风险评分负荷与精神病性易感性及氯氮平使用的关联

Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

这项多中心观察性队列研究对2344名参与者(包括557名使用氯氮平的精神分裂症谱系障碍患者、350名使用其他抗精神病药的患者、542名父母、574名同胞和321名无关健康对照)进行6年随访,发现精神分裂症多基因风险评分(PRS-SCZ)负荷在各组间存在差异,使用氯氮平的患者PRS-SCZ负荷最高,且PRS-SCZ与氯氮平处方的可能性正相关。

要点

  • 使用氯氮平的患者PRS-SCZ负荷最高,风险比(RR)为3.24。
  • PRS-SCZ与氯氮平相对于其他抗精神病药的处方可能性正相关(OR=1.41)。
  • PRS-SCZ可能有助于精神分裂症谱系障碍的早期干预和预后研究。

核心结论

  • PRS-SCZ负荷在精神分裂症谱系障碍患者、其亲属及无关健康对照间存在差异,使用氯氮平的患者处于PRS-SCZ负荷的最高端。
  • PRS-SCZ与氯氮平处方可能性较高相关。

研究设计与样本

  • 多中心、观察性队列研究,随访6年,纳入精神分裂症谱系障碍患者(使用氯氮平或其他抗精神病药)、其父母和同胞及无关健康对照。
  • 数据收集于2004年至2021年,分析于2021年10月至2022年9月。
  • 共2344名参与者(平均年龄36.95岁,标准差14.38;女性994人,占42.4%)。

主要发现

  • 使用氯氮平的患者PRS-SCZ风险比(RR)为3.24(95% CI,2.76-3.81;P=2.47×10^-46)。
  • 使用其他抗精神病药的患者RR为2.30(95% CI,1.95-2.72;P=3.77×10^-22)。
  • 父母RR为1.44(95% CI,1.25-1.68;P=1.76×10^-6),同胞RR为1.40(95% CI,1.21-1.63;P=8.22×10^-6)。
  • PRS-SCZ与氯氮平相对于其他抗精神病药的使用正相关(OR=1.41;95% CI,1.22-1.63;P=2.98×10^-6)。

关键数值与推荐

  • 使用氯氮平的患者PRS-SCZ风险比(RR)为3.24(95% CI,2.76-3.81;P=2.47×10^-46)。
  • 使用其他抗精神病药的患者RR为2.30(95% CI,1.95-2.72;P=3.77×10^-22)。
  • 父母RR为1.44(95% CI,1.25-1.68;P=1.76×10^-6),同胞RR为1.40(95% CI,1.21-1.63;P=8.22×10^-6)。
  • PRS-SCZ与氯氮平相对于其他抗精神病药的使用正相关(OR=1.41;95% CI,1.22-1.63;P=2.98×10^-6)。

临床怎么用

  • PRS-SCZ可能为精神分裂症谱系障碍的早期干预和预后研究提供信息。
  • PRS-SCZ可能有助于个体化抗精神病药治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Predictors consistently associated with psychosis liability and course of illness in schizophrenia (SCZ) spectrum disorders (SSD), including the need for clozapine treatment, are lacking. Longitudinally ascertained medication use may empower studies examining associations between polygenic risk scores (PRSs) and pharmacotherapy choices. OBJECTIVE: To examine associations between PRS-SCZ loading and groups with different liabilities to SSD (individuals with SSD taking clozapine, individuals with SSD taking other antipsychotics, their parents and siblings, and unrelated healthy controls) and between PRS-SCZ and the likelihood of receiving a prescription of clozapine relative to other antipsychotics. DESIGN, SETTING, AND PARTICIPANTS: This genetic association study was a multicenter, observational cohort study with 6 years of follow-up. Included were individuals diagnosed with SSD who were taking clozapine or other antipsychotics, their parents and siblings, and unrelated healthy controls. Data were collected from 2004 until 2021 and analyzed between October 2021 and September 2022. EXPOSURES: Polygenic risk scores for SCZ. MAIN OUTCOMES AND MEASURES: Multinomial logistic regression was used to examine possible differences between groups by computing risk ratios (RRs), ie, ratios of the probability of pertaining to a particular group divided by the probability of healthy control status. We also computed PRS-informed odd ratios (ORs) for clozapine use relative to other antipsychotics. RESULTS: Polygenic risk scores for SCZ were generated for 2344 participants (mean [SD] age, 36.95 years [14.38]; 994 female individuals [42.4%]) who remained after quality control screening (557 individuals with SSD taking clozapine, 350 individuals with SSD taking other antipsychotics during the 6-year follow-up, 542 parents and 574 siblings of individuals with SSD, and 321 unrelated healthy controls). All RRs were significantly different from 1; RRs were highest for individuals with SSD taking clozapine (RR, 3.24; 95% CI, 2.76-3.81; P = 2.47 × 10-46), followed by individuals with SSD taking other antipsychotics (RR, 2.30; 95% CI, 1.95-2.72; P = 3.77 × 10-22), parents (RR, 1.44; 95% CI, 1.25-1.68; P = 1.76 × 10-6), and siblings (RR, 1.40; 95% CI, 1.21-1.63; P = 8.22 × 10-6). Polygenic risk scores for SCZ were positively associated with clozapine vs other antipsychotic use (OR, 1.41; 95% CI, 1.22-1.63; P = 2.98 × 10-6), suggesting a higher likelihood of clozapine prescriptions among individuals with higher PRS-SCZ. CONCLUSIONS AND RELEVANCE: In this study, PRS-SCZ loading differed between groups of individuals with SSD, their relatives, and unrelated healthy controls, with patients taking clozapine at the far end of PRS-SCZ loading. Additionally, PRS-SCZ was associated with a higher likelihood of clozapine prescribing. Our findings may inform early intervention and prognostic studies of the value of using PRS-SCZ to personalize antipsychotic treatment.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lin BD, Pinzón-Espinosa J, Blouzard E, et al. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia. JAMA Psychiatry. 2023. PMID: 36542388. doi:10.1001/jamapsychiatry.2022.4234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。